Search | Clinical Trials Finder

Conditions: Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
Interventions: 7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.; Other
Lead sponsor: Sunnybrook Health Sciences Centre; Other
Eligibility: 18 Years and older
Enrollment: 3,622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Bacteremia
Interventions: Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bacteremia, Pseudomonas Infections
Interventions: Blood draws, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bile Duct Stricture, Choledocholithiasis
Interventions: Blood draw for culture; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Rajesh Lalla; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Bacteremia
Interventions: Effect of Amoxicillin on bacteremia following a single-tooth extraction; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions: E5564; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 17
States / cities: Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more

Conditions: Bacteremia
Interventions: Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL; Drug
Lead sponsor: Satellite Healthcare; Other
Eligibility: Not listed
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: Oritavancin Injection; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Interventions: Oritavancin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemodialysis Catheter-related Bacteremia
Interventions: tigecycline, N-acetylcysteine, heparin combination, guide-wire exchange; Drug · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Catheter-Related Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Saint Davids, Pennsylvania

Conditions: Fatigue, End Stage Renal Disease (ESRD)
Interventions: Lipidose, Placebo; Drug
Lead sponsor: Sepsicure; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Catheter; Infection (Indwelling Catheter), Catheter Infection, Catheter-Related Infections, Catheter Bacteraemia, Urinary Tract Infections
Interventions: Povidone-iodine irrigation; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions: Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg; Drug
Lead sponsor: Entasis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more

Conditions: Gram-negative Bacteremia
Interventions: Accelerate PhenoTest™ BC Kit, Standard Culture and AST; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • Rochester, Minnesota

Conditions: Infective Endocarditis
Interventions: daptomycin, daptomycin and gentamicin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 13 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more

Conditions: Neonatal Sepsis
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 3 Days and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Charlottesville, Virginia

Conditions: Preterm Birth, Preterm Labor, Bacteremia, Preterm Premature Rupture of Fetal Membranes
Interventions: Prenatal vitamin-mineral containing 3 mg fluoride, Prenatal vitamin-mineral containing 0 mg fluoride; Drug · Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions: Vancomycin, Ceftaroline, Daptomycin, Linezolid; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions: Exebacase; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Butte, Montana • Toledo, Ohio

Search by objective public record fields.

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Chart Review of Outcome of Treatment for S. Aureus Bacteremia

Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)

Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).

Dental Study in Cancer Patients With Central Venous Catheters

Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

Prophylactic Antimicrobial Catheter Lock

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

Treatment of Hemodialysis Catheter-Related Bacteremia

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Lipid Infusion in Dialysis Patients With Endotoxemia

Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia